OCT IMAGING OF SUB-SCLERAL CHANNELS CREATED WITH FEMTOSECOND

使用飞秒创建的巩膜下通道 OCT 成像

• 批准号: 8362662
• 负责人: ZHONGPING CHEN
• 金额: $ 2.07万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-04-01 至 2012-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8362662
• 关键词: Affect; Animal Model; Animals; Biotechnology; Blindness; Cadaver; Cell Death; Cicatrix; Doctor of Philosophy; Drainage procedure; Evaluation; Eye; Eyedrops; Funding; Fundus; General Anesthesia; Glaucoma; Grant; IACUC; Image; In Vitro; Laboratories; Lasers; Life; Liquid substance; Location; Longevity; Measurement; Michigan; Modification; National Center for Research Resources; Normal Range; Operative Surgical Procedures; Oryctolagus cuniculus; Principal Investigator; Procedures; Production; Property; Protocols documentation; Recovery; Research; Research Infrastructure; Research Personnel; Resources; Shapes; Source; Techniques; Technology; Testing; Tissues; United States National Institutes of Health; Universities; Wound Healing; aqueous; cost; in vitro Model; in vivo; pressure; research study

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Femtosecond lasers can be delivered through transparent and translucent tissue to perform high precision surgical procedures without damage to the superficial or adjacent tissues. These unique properties of the femtosecond laser-tissue interactions provides considerable potential advantage over traditional laser treatments used for glaucoma. Glaucoma is one of the leading causes of blindness with over 2 million people affected in the US alone. The condition is characterized by increased pressure in the eye which causes gradual, permanent cell death in the fundus resulting in blindness. Treatment of glaucoma focuses on lowering the eye pressure by reducing the production of fluid in the eye that maintains the pressure (aqueous) or increasing the drainage of this fluid out of the eye. At present, the traditional treatment would include use of eye drops, laser, or surgery however, use of these treatments may be cumbersome and poses a lot of complications such as scar formation especially after surgery. We hypothesize that the application of the femtosecond laser may be used to treat glaucoma. Among several potential advantages over the traditional glaucoma treatments the most important is its ability to create drainage channels for aqueous outflow without collateral damage to the overlying or adjacent tissue. This will likely increase the longevity of the drainage channel that can maintain eye pressure within normal range. To test our hypothesis, we propose the evaluation of femtosecond laser technology for the creation of drainage channels in an in vivo animal model. An in-vitro model of the aqueous outflow was already created by the same group in another laboratory (University of Michigan) as an initial step to understand the effect of femtosecond laser created drainage channels on the aqueous outflow in cadaver eyes. The best shape and depth of the channel was obtained from this cadaver eye experiment. After the in-vitro study, it is necessary to establish the efficacy of the femtosecond laser technology for the creation of drainage channels in a live animal model. Additionally, the efficacy of the drainage channels for decreassing intraoccular pressure can also evaluated in vivo. Aims: 1. Demonstrate the efficacy of femtosecond laser glaucoma treatment and optimize the procedure using in vivo animal models and standard measurement techniques of the aqueous outflow 2. Investigate longevity and patency of femtosecond laser-created outflow channels by performing wound-healing studies using in vivo animal models Following general anesthesia at another location, each rabbit will be transported to BLI for OCT imaging of its eyes and then returned to the investigator's lab for recovery. All animal studies will be performed under and in accordance with the UCI IACUC approved animal protocol #2005-2567, and that a copy of that protocol, the IACUC approval and any approved modifications of the protocol will be provided to BLI. Tibor Juhasz, PhD (Ph: 949-824-8769) will be designated as the responsible party for oversight of the animal procedures at BLI.

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 飞秒激光可以通过透明和半透明的组织输送，以执行高精度的外科手术，而不会损伤浅表或邻近组织。 飞秒激光-组织相互作用的这些独特性质提供了与用于青光眼的传统激光治疗相比相当大的潜在优势。青光眼是导致失明的主要原因之一，仅在美国就有超过200万人受到影响。这种情况的特征是眼睛压力增加，导致眼底细胞逐渐永久死亡，导致失明。青光眼的治疗集中在通过减少维持压力的眼睛中的液体（水）的产生或增加这种液体从眼睛中的排出来降低眼压。 目前，传统的治疗方法包括使用眼药水、激光或手术，然而，使用这些治疗方法可能很麻烦，并且会造成很多并发症，例如疤痕形成，特别是在手术后。我们假设飞秒激光的应用可用于治疗青光眼。在与传统青光眼治疗相比的几个潜在优势中，最重要的是其能够为房水流出创建引流通道，而不会对覆盖或邻近组织造成附带损伤。这可能会增加引流通道的寿命，使眼压保持在正常范围内。 为了验证我们的假设，我们建议在体内动物模型中评估飞秒激光技术用于创建引流通道。作为了解飞秒激光创建的引流通道对尸体眼中房水流出的影响的第一步，同一组在另一个实验室（密歇根大学）创建了体外房水流出模型。 从该尸体眼实验中获得了通道的最佳形状和深度。 体外研究后，有必要在活体动物模型中确定飞秒激光技术创建引流通道的有效性。此外，还可以在体内评价引流通道降低眼内压的功效。 目的： 1.使用体内动物模型和标准房水流出量测量技术证明飞秒激光青光眼治疗的有效性并优化手术 2.通过使用体内动物模型进行伤口愈合研究，研究飞秒激光创建的流出通道的寿命和通畅性 在另一个位置全身麻醉后，将每只家兔运送至BLI对其眼睛进行OCT成像，然后返回研究者实验室进行恢复。 所有动物研究将根据UCI IACUC批准的动物方案#2005-2567进行，并将向BLI提供该方案的副本、IACUC批准和任何批准的方案修改。Tibor Juhasz博士（Ph：949-824-8769）将被指定为负责监督BLI动物程序的负责人。